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Background: Acute exacerbation (AE) is a major cause of death in idiopathic pulmonary fibrosis
(IPF). However, little is known about sensitive biomarkers for predicting AE. The aim of our
study was to investigate the significance of KL-6 and CC-Chemokine Ligand 18 (CCL18) as pre-
dictors for AE of IPF.
Methods: We prospectively collected a total of 77 patients with IPF. Serum levels of KL-6 and
CCL18 were measured by ELISA. The correlation between baseline serum levels of the markers
and the incidence of AE was evaluated.
Results: Thirteen (17%) patients experienced AE during follow-up. Baseline serum KL-6 levels
were significantly higher in patients who developed AE than in patients with stable IPF
(p < 0.0001), whereas serum CCL18 levels showed no difference between these groups
(p Z 0.13). At a cut-off level of 1300 U/mL for KL-6, the sensitivity, specificity, accuracy
and likelihood ratio to predict AE were 92%, 61%, 66% and 2.36, respectively. In the Kaplanof Pneumology/Allergy, Ruhrlandklinik, University Hospital, University Duisburg-Essen, Tueschener
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onset of AE (p Z 0.002), whereas CCL18 showed no predictive value (p Z 0.11). In the multi-
variate analysis, baseline serum KL-6 (both continuous and at a cut-off level of 1300 U/mL)
was an independent predictive factor for AE after adjustment for age, sex, smoking history and
%vital capacity (hazard ratio Z 1.001, 18.8; p Z 0.010, 0.008, respectively).
Conclusions: Baseline serum KL-6 level is a sensitive predictor for the onset of AE in IPF.
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Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic
lung disease of unknown etiology with a median survival of
3e5 years [1,2]. Although the clinical course of IPF is usu-
ally chronic, some patients may experience acute respira-
tory worsening, termed acute exacerbation (AE) [1,3,4].
AE of IPF (AE-IPF) is defined by acute worsening of
symptoms, the presence of new ground glass abnormalities
on computed tomography of the chest, and the absence ofidentifiable causes including infection, left heart failure or
pulmonary embolism [3]. The prognosis of AE-IPF is poor,
usually leading to death within a few weeks to months
[1,3,4]. The precise incidence, risk factors and outcomes of
AE-IPF remain unknown [3]. Although sensitive biomarkers
predicting AE are necessary for early interventions, little is
known about sensitive biomarkers predicting AE-IPF.
Serum levels of KL-6 and CC-chemokine ligand 18
(CCL18) are potential biomarkers to predict prognosis of
IPF. KL-6, a complex sialo-carbohydrate glycoprotein pre-
sent in the human MUC1 mucin, is a sensitive biomarker for
type II alveolar epithelial proliferation and/or injury [5].
Serum levels of KL-6 are increased in patients with various
interstitial lung diseases including IPF [5,6]. Serial changes
of serum KL-6 have been shown to predict the short-term
prognosis of rapid deterioration in IPF [7].
CCL18, a CC-chemokine produced by human myeloid
cells, is secreted mainly by the M2 phenotype of alveolar
macrophages activated by Th2 cytokines and interleukin
(IL)-10 [8]. CCL18 plays an important role in the fibroblast
proliferation and collagen production in IPF [8]. Serum
CCL18 levels have been reported to be associated with
change in lung function and survival in IPF [9].
The aim of the present study was to investigate the
significance of serum KL-6 and CCL18 as predictive bio-
markers for AE-IPF. Some of the results of these studies
have been previously reported in the form of an abstract
[10].
Methods
Study subjects
The subjects consisted of 77 consecutive patients diag-
nosed as having IPF according to the official American
Thoracic Society (ATS)/European Respiratory Society (ERS)/
Japanese Respiratory Society (JRS)/Latin American
Thoracic Association (ALAT) statement [11] who were
admitted to Ruhrlandklinik (Essen, Germany) between 2006
and 2008. All patients were reviewed for the current study
to validate the diagnosis using the current criteria, and 71
(92%) patients were classified into definite IPF according to
the current guidelines. The IPF diagnosis in 6 (8%) patients
was confirmed by the histopathological examinations of
surgical lung biopsy. The control group for serum KL-6 levels
consisted of 155 age- and sex-matched healthy individuals.
All subjects enrolled were Caucasians.
All patients were prospectively enrolled, and serum
samples were obtained from every patient at the
Table 1 Baseline characteristics of the enrolled IPF pa-
tients with/without AE-IPF.
Without
AE-IPF
With
AE-IPF
p-Valuea
n 64 13
Age, yr 70  8 67  5 0.14
Sex, male/female 47/17 11/2 0.50
Smoking, current/non 9/58 2/11 0.90
Baseline %VC, % 68  15 54  17 0.003
Baseline %TLC, % 64  12 55  10 0.048
Baseline %DLCO, % 44  14 43  10 0.87
Baseline A-aDO2, mmHg 29  10 30  17 0.73
Delay between first
symptoms and
KL-6 measurement,
months
69  169 41  26 0.65
33 (11e65) 44 (31e60)
Delay between IPF
diagnosis and KL-6
measurement, months
30  45 31  20 0.17
12 (0e40) 29 (21e43)
Therapy, n (%)
- Prednisolone 50 (78) 12 (92) 0.44
- Azathioprine 46 (72) 10 (77) >0.99
- N-acetylcysteine 45 (70) 10 (77) 0.75
- Cyclophosphamide 6 (9) 2 (15) 0.62
- Others 2 (3) 2 (15) 0.13
Data are expressed as mean  standard deviation or median
(interquartile range).
IPF, idiopathic pulmonary fibrosis.
AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis.
a ManneWhitney’s U test or chi-square test.
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diagnosis in 22 (29%) patients and during follow-up in 55
(71%) patients. Samples were stored at 80 C until ana-
lyses of KL-6 and CCL18. Serum levels of KL-6 and CCL18
were measured by commercially available enzyme-linked
immunosorbent assay (ELISA) (Eitest KL-6 ELISA kit, EIDIA
Co., Ltd., Tokyo, Japan; Human CCL18/PARC Quantikine
ELISA Kit, R&D Systems, MN). All measurements were per-
formed in duplicate, and the data were expressed as the
mean value. The correlation between baseline serum levels
of these biomarkers and the incidence of AE was evaluated.
The study was approved by the Institutional Review
Board of Ruhrlandklinik (IRB 06-3170) and Hiroshima Uni-
versity Hospital (IRB 326) and conducted in accordance with
the ethical standards established in the Helsinki Declara-
tion of 1975. Written informed consent was obtained from
each participant in this study.
Pulmonary function tests
Pulmonary function variables were analyzed by using
spirometry (ZAN 400 Sniff, ZAN Messgeraete GmbH, Kerpen
Sindorf, Germany) according to the ATS/ERS recommen-
dation [12]. Arterial blood gas was analyzed by using ABL
800 Flex (Radiometer GmbH, Brønshøj, Denmark). Values
were expressed as percentages of predicted normal values.
Definition of AE
Definite AE was defined as previously described [3]. In brief,
patients had a previous or concurrent diagnosis of IPF and
presented with unexpected worsening of dyspnea within 30
days and newly developed bilateral ground-glass abnor-
malities on high-resolution computed tomography (HRCT)
with no evidence of pulmonary infection by endotracheal
aspirate or bronchoalveolar lavage fluid (BALF). Suspected
AE was defined as above, but data on endotracheal aspirate
or BALF examination were missing. Based on the findings of
CT, electrocardiogram, echocardiography and the repeated
culture of respiratory aspirates, patients with left heart
failure, pulmonary embolism, or identifiable cause of acute
lung injury were excluded from definite and suspected AE.
Among the 77 patients enrolled, 4 (5%) patients experi-
enced a definite AE, and 9 (12%) patients experienced a
suspected AE. For the purpose of data analysis, both defi-
nite and suspected AE were included as cases of AE [13].
Statistical analysis
Data are expressed as mean  standard deviation (SD).
Comparison of non-normally distributed variables between
groups was done with the ManneWhitney’s U test. Com-
parison of categorical variables between two groups was
done with the chi-square test. Correlation between 2
groups was analyzed with linear regression analysis. The
probability of AE was estimated with the KaplaneMeier
method, and the differences in AE-free rates were evalu-
ated by log-rank test. Multivariate analysis of predictive
factors for AE-IPF was done using the Cox regression hazard
model. The predictive value for AE-IPF of each marker was
evaluated by the C statistics. All statistical analyses weredone using SPSS version 13.0 for Windows (SPSS Inc., Chi-
cago, IL). Differences were considered statistically signifi-
cant when the p-value was <0.05.
Results and discussion
Patient characteristics
There were 58 males and 19 females with a mean age of
69  8 years. There were 34 never smokers, 32 former
smokers and 11 current smokers, respectively. No signifi-
cant differences were observed in sex and age distribution
and therapeutic regimens between the groups (Table 1).
The mean follow-up period was 3.0  2.1 years (median 2.7
years, interquartile range (IQR) 1.1e4.4 years). Among the
77 patients with IPF, 4 (5%) patients experienced a definite
AE, and 9 (12%) patients experienced a suspected AE
(Additional file 1). The median duration before the onset of
AE-IPF was 33 months (IQR 13e53 months). The 1-yr inci-
dence of AE-IPF was 7%.
Patients with AE-IPF had a higher proportion of smokers,
a lower vital capacity (VC) and a lower total lung capacity
(TLC) compared to those without (p Z 0.031, p Z 0.003,
pZ 0.048, respectively, Table 1). There were no significant
differences in the delay between the time of first symptoms
until KL-6 measurement (median 44 months (IQR 31e60
months), 33 months (IQR 11e65 months), respectively;
p Z 0.65) and in the delay between the time of IPF
Figure 1 Distribution of baseline serum levels of KL-6 and CCL18. Scatter plot graphs showing the distribution of baseline
serum levels of KL-6 (A) and CCL18 (B) in healthy subjects (n Z 155), patients without AE-IPF (n Z 64) and patients with AE-IPF
(n Z 13). IPF, idiopathic pulmonary fibrosis; AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis.
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21e43 months), 12 months (IQR 0e40 months), respec-
tively; p Z 0.17) between the patients with AE-IPF and
without AE-IPF (Table 1).
Baseline serum KL-6/CCL18 levels
The distributions of baseline serum KL-6 and CCL18 levels
are shown in Fig. 1. Serum KL-6 levels were significantly
higher in patients with AE-IPF than in those without or in
healthy subjects (patients with AE-IPF, 2528  1645 U/mL;
patients without AE-IPF, 1584  1000 U/mL; healthy sub-
jects, 299  97 U/mL; p < 0.0001, p < 0.0001, respec-
tively). Serum CCL18 levels were also significantly higher
in patients with AE-IPF than in healthy subjects, however,
no significant difference was observed between patients
with and without AE-IPF (patients with AE-IPF,
229  52 ng/mL; patients with stable IPF, 207  42 ng/
mL; healthy subjects, 132  51 ng/mL; p Z 0.13,
p < 0.0001, respectively).
Correlation with pulmonary function variables
The correlation between baseline serum KL-6 levels and
pulmonary function variables are shown in Fig. 2. TLC%
predicted (%TLC) and diffusion lung capacity for carbon
monoxide (%DLCO) were inversely correlated with serum
KL-6 levels (r Z 0.408, p Z 0.001; r Z 0.263,
pZ 0.042, respectively; Fig. 2(B and C). VC% predicted (%
VC) and alveolar-arterial oxygen gradient (A-aDO2) showed
no correlation with serum KL-6 levels Fig. 2(A and D).
Predictive value for acute exacerbation
Receiver operating characteristic (ROC) curve analysis was
used to evaluate the sensitivity, specificity and accuracy of
serum KL-6 and CCL18 levels for predicting AE-IPF. The
larger area under the curve was found for serum KL-6 with0.736 (95% confidence interval (CI), 0.61 to 0.85;
pZ 0.008) compared with serum CCL18 with 0.651 (95%CI,
0.48 to 0.82; pZ 0.09). When the cut-off levels were set at
the closest point to 100% sensitivity and 100% specificity,
the levels for predicting AE-IPF were 1300 U/mL for KL-6
(sensitivity, 92%; specificity, 61%; accuracy, 66%; likeli-
hood ratio, 2.36, respectively) and 212 ng/mL for CCL18
(sensitivity, 77%; specificity, 64%; accuracy, 66%; likelihood
ratio, 2.14, respectively).
Correlation with acute exacerbation
The KaplaneMeier analysis showed that higher serum KL-6
was associated with a shorter follow-up period before the
onset of AE-IPF (p Z 0.002, Fig. 3A). In contrast, serum
CCL18 showed no correlation with the follow-up period
before AE-IPF (p Z 0.11, Fig. 3B). There was no correla-
tion between baseline serum KL-6 and time to AE-IPF
(r Z 0.31, p Z 0.30). However, if the patients were
divided into 2 groups with a cut-off level of 1300 U/mL for
KL-6, the patients with higher KL-6 levels experienced
earlier onset of AE-IPF than the patients with lower KL-6
levels (median 29 months (IQR 7e41 months), 44 months
(IQR 22e70 months), respectively; pZ 0.013). There were
no significant differences in the delay between the time of
first symptoms until KL-6 measurement (median 35 months
(IQR 15e56 months), 33 months (IQR 8e72 months),
respectively; pZ 0.74) and in the delay between the time
of IPF diagnosis until KL-6 measurement (median 9 months
(IQR 0e49 months), 21 months (IQR 2e35 months),
respectively; p Z 0.74) between the patients with higher
and lower baseline KL-6 levels.
In the univariate survival analysis, %VC (continuous)
(hazard ratio (HR), 0.93, 95%CI, 0.89e0.97; p Z 0.001),
serum KL-6 levels (continuous) (HR, 1.001, 95%CI,
1.000e1.001; p Z 0.002) and serum KL-6 levels 1300 U/
mL (HR, 12.1, 95%CI, 1.52e100; pZ 0.018) were associated
with the risk of AE-IPF, whereas no correlations were found
between the risk of AE-IPF and age, sex, smoking, %DLCO
Figure 2 Correlation between KL-6 and pulmonary function variables. Scatter plot graphs showing the correlation of KL-6 with
%VC (A), %TLC (B), %DLCO (C) and A-aDO2 (D). VC, vital capacity; TLC, total lung capacity; DLCO, Diffusion lung capacity for carbon
monoxide; A-aDO2, alveolar-arterial oxygen gradient.
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vival analysis, %VC (continuous), serum KL-6 levels
(continuous) and serum KL-6 levels 1300 U/mL were
independently associated with the risk of AE-IPF (%VC: HR,
0.92, 95%CI, 0.87e0.97, p Z 0.004; KL-6 (continuous): HR,
1.001, 95%CI, 1.000e1.001, p Z 0.010; KL-6  1300 U/mL:
HR, 11.8, 95%CI, 1.43e97.8, p Z 0.022) after adjustment
for age, sex, smoking history and the use of triple therapy
(prednisone, azathioprine and N-acetylcysteine).
In our cohort, the C statistic for predicting AE-IPF
significantly increased when KL-6 and %VC were sepa-
rately incorporated into a model with covariates (C sta-
tistic, 0.708, 0.708; 95%CI, 0.544e0.872, 0.549e0.868;
p Z 0.021, 0.021, respectively) (Table 3). However, the
addition of CCL18 to the model with covariates did not
improve the C statistic for predicting AE-IPF. When the
combination of KL-6 and %VC were incorporated into a
model with covariates, the C statistic was highest (C sta-
tistic, 0.747; 95%CI, 0.575e0.919; p Z 0.006).Discussion
This study showed that baseline serum KL-6 levels were
significantly higher in patients who experienced an AE-IPF
during the follow-up compared to those who remained
free from an AE-IPF. There was no significant difference in
serum CCL18 levels between patients with AE-IPF and
those without. Baseline serum KL-6 levels were inversely
correlated with %TLC and %DLCO. In the multivariateanalysis, baseline serum KL-6 level (both as continuous
value and at the cut-off levels of 1300 U/mL) and
decreased %VC were independent risk factors for the
development of AE-IPF. KL-6 is the first biomarker that
demonstrated a predictive value for the risk of AE in pa-
tients with IPF.
Collard et al. recently reported that suspected AE-IPF
were clinically indistinguishable from definite AE-IPF, and
were associated with a similarly high risk of disease pro-
gression and short-term mortality in IPF [13]. In their cohort
of 180 IPF patients, 4 (2%) cases were classified as definite
AE-IPF and 14 (8%) as suspected AE-IPF. Thus, the majority
of events in that trial were only suspected and not definite
AE-IPF. In our cohort of 77 IPF patients, 4 (5%) cases were
classified as definite AE-IPF and 9 (12%) as suspected AE-IPF.
The proportions of definite and suspected AE-IPF were
similar to their study. Because the enrollment of both
definite and suspected AE-IPF appears to be useful as
outcome measures in clinical trials, we have adopted these
enrollment criteria in our study.
Previous studies have reported several clinical, physio-
logical and radiological factors associated with mortality in
IPF. The factors include age, sex, smoking history, duration
of symptoms, responsiveness to therapy, histopathologic
findings, HRCT findings [14], 6-min walking test and base-
line and decline in DLCO and FVC [15]. Genetic factors may
be important in the manifestation of in IPF. Previous studies
reported that mutations in MUC5B gene [16], surfactant
protein genes [17], erythrocyte complement receptor 1 [18]
and telomerase reverse transcriptase (hTERT) [19] were
Figure 3 KaplaneMeier analysis for the onset of acute exacerbation of IPF. Patients with baseline serum KL-6 level 1300 U/
mL showed shorter duration before the onset of acute exacerbation compared with patients with baseline serum KL-6 level
<1300 U/mL (A), whereas CCL18 showed no statistical impact on the prediction of acute exacerbation (B).
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ated only with the mortality in IPF, and none of these
markers have shown to be associated with the risk of AE-IPF
[16e19].
Serum levels of several biomarkers are increased in AE-
IPF, which are likely involved in the pathogenesis of AE-IPF.
Collard et al. demonstrated that serum levels of KL-6,
surfactant protein-D (SP-D), von Willebrand factor, IL-6,
total protein C, thrombomodulin and plasminogen activator
inhibitor-1 (PAI-1) were significantly higher in AE-IPF than in
stable IPF [20]. Other biomarkers including high mobility
group box 1 (HMGB1), monocyte chemotactic protein-1
(MCP-1), soluble ST2 protein [21], a-defensin [22], or
CCNA2 gene [22] might be candidates for predicting the risk
of AE-IPF.
Increased levels of biomarkers may be predictive of
survival in AE-IPF. Richards et al. demonstrated in 241Table 2 Univariate and multivariate analyses for the risk
of AE-IPF.
Variables b HR (95%CI) p-Value
Univariate analysis
Age (continuous) 0.03 0.98 (0.90 e 1.05) 0.51
Male sex 0.95 2.58 (0.33 e 20.4) 0.37
Current smoker 0.38 1.46 (0.31 e 6.90) 0.63
Use of triple therapy 0.43 1.53 (0.43 e 5.43) 0.51
%VC (continuous) 0.07 0.93 (0.89 e 0.97) 0.001
%DLCO (continuous) 0.01 0.99 (0.92 e 1.07) 0.83
KL-6 (continuous) 0.00 1.00 (1.00 e 1.00) 0.002
KL-6 1300 U/mL 2.49 12.1 (1.52 e 100) 0.018
CCL18 (continuous) 0.01 1.01 (0.99 e 1.02) 0.47
CCL18 212 ng/mL 1.07 2.92 (0.76 e 11.4) 0.12
Multivariate analysisa
%VC (continuous) 0.08 0.92 (0.87 e 0.97) 0.004
KL-6 (continuous) 0.00 1.00 (1.00 e 1.00) 0.009
KL-6 1300 U/mL 2.47 11.8 (1.43 e 97.8) 0.022
HR, hazard ratio; CI, confidence interval; VC, vital capacity.
DLCO, diffusion lung capacity for carbon monoxide.
a Adjusted for age, sex, smoking history and the use of triple
therapy(prednisone, azathioprine and N-acetylcysteine).patients with stable IPF that high plasma levels of matrix
metalloproteinase (MMP)-7, intercellular adhesion mole-
cule (ICAM)-1 and IL-8 predicted poor overall survival [23].
Korthagen et al. have shown in 85 patients with stable IPF
that high serum and BALF levels of YKL-40 predicted poor
survival [24]. Tachibana et al. demonstrated in 19 patients
with AE-IPF that increased serum IL-7, an inhibitor of
transforming growth factor-b (TGF-b) production and
fibroblast signaling, was associated with better prognosis in
AE-IPF [25]. Although these biomarkers might be candidates
as predictors for AE-IPF, no biomarker has clearly shown a
predictive utility for the onset of AE-IPF.
In this study, we focused on the utility of KL-6 and CCL18
as candidates of predictive biomarkers for the onset of AE-
IPF, because both biomarkers have shown diagnostic and
prognostic utility in stable IPF [9,26]. Increased serum KL-6
levels 1000 U/mL was found to be predictive of poor
prognosis in stable IPF [26]. Yokoyama et al. demonstrated
in 14 patients with AE-IPF that changes in serum KL-6 levels
predicted the response to treatment [7]. Fujimoto et al.
showed in 60 patients with AE-IPF that increased partial
pressure of carbon dioxide (PaCO2), increased serum KL-6Table 3 C statistic for Cox regression models predicting
AE-IPF.
Biomarkers C statistic (95%CI) p-Value
Covariatesa
only
0.649 (0.460 e 0.839) Referent
Covariatesa
plus%VC
0.811 (0.656 e 0.965) 0.002
Covariatesa
plus KL-6
0.770 (0.625 e 0.914) 0.006
Covariatesa
plus CCL18
0.663 (0.505 e 0.820) 0.10
Covariatesa
plus%VC
and KL-6
0.854 (0.701 e 1.006) 0.0003
a Covariates included age (continuous variable), sex, smoking
history and the use of triple therapy (prednisone, azathioprine
and N-acetylcysteine).
Baseline KL-6 predicts risk for AE-IPF 1037level and severer HRCT score were correlated with poor
survival. In the multivariate analysis, however, only HRCT
score was an independent prognostic factor for AE-IPF [14].
Prasse et al. demonstrated in 72 patients with IPF that
baseline serum CCL18 levels predicted the change in %TLC
and %FVC at 6-month follow-up, and baseline serum
CCL18 > 150 ng/mL was an independent predictor of poor
prognosis with the HR of 8.0 [9]. In this study, we showed
for the first time that baseline serum KL-6 level 1300 U/
mL is an independent predictive biomarker for the onset of
AE-IPF, whereas CCL18 was not able to predict the onset of
AE-IPF. Although the mechanisms of increased serum CCL18
levels in patients with IPF have not been well known, the
excessive production of CCL18 and/or the change in
macrophage activation might be associated with the in-
crease in serum CCL18 levels [9]. CCL18 appears to be a
sensitive biomarker predicting the chronic progression of
IPF and the subsequent survival; however, CCL18 does not
seem to be sensitive to predict acute worsening of IPF. This
discrepant finding of CCL18 might be associated with the
different mechanisms involved in chronic progression of IPF
and in AE-IPF.
High sensitivity (92%) and low specificity (61%) of KL-6
with a cut-off level of 1300 U/mL for predicting AE-IPF
indicate that high KL-6 is predictive of high risk of AE-IPF,
although low KL-6 is not predictive of low risk of AE-IPF.
Therefore, clinicians should most carefully monitor the
clinical course and pulmonary dysfunction of the patients,
and should prepare for prompt treatment including high-
dose corticosteroid therapy in patients with higher baseline
KL-6 levels. However, clinicians should also be aware that
serum KL-6 level with a cut-off level of 1,300 U/mL shows a
high false-positive rate (39%).
The mechanisms of the increase in serum KL-6 levels are
thought to include an overexpression of KL-6 by regener-
ating alveolar type II pneumocytes, and/or increased
permeability following disintegration of the alveolar-vessel
barrier [27]. The epitope of KL-6 monoclonal antibody in-
volves sulfate and sialic acid residues, which may be
regulated by Gal6ST gene [28]. Collard et al. have sug-
gested that the rapid alteration in epithelial cell integrity,
cellular inflammation, cytokines, MMPs, and coagulation
components may be involved in the pathogenesis of AE-IPF
[3]. An acute direct stress to the lung leads to diffuse
alveolar damage with a subsequent acceleration of the
fibroproliferation in AE-IPF. The severity and rapidity of
diffuse alveolar damage are likely to be correlated with the
subsequent increase in serum KL-6 level. The purified KL-6
molecule has chemotactic, proliferative and anti-apoptotic
effects on fibroblasts in vitro [29]. Persistent high con-
centration of KL-6 in the alveolar space is highly likely to
evoke a high potential for fibrosis. By stimulating the
alveolar epithelial cells and/or fibroblasts by yet unknown
triggers in AE-IPF, KL-6 may contribute to accelerated
epithelial damage, leading to fibrosis. Whether KL-6 levels
are related to bronchiolar hyperplasia or honeycomb
changes on HRCT is an open question and need to be
addressed in future studies.
In this study, we have defined the cut-off level for KL-6
as 1300 U/mL, whereas most of the previous studies defined
the cut-off level for KL-6 as 1000 U/mL [26]. The relatively
higher cut-off level for KL-6 compared with previous studiesis likely to be associated with a genetic difference [30]. The
distribution of the rs4072037 genotype, which is associated
with the range of serum KL-6 levels, is different in Cauca-
sian and Japanese cohorts, leading to higher normal values
in Caucasian than in Japanese subjects. The patients
enrolled in this study were Caucasians, whereas most of the
previous studies enrolled Japanese patients.
A limitation is the small number of patients enrolled.
Larger, potentially multicenter prospective studies are
needed to validate the results of our study. The other
limitation is the lack of data in the chronologic changes of
KL-6 and CCL18 levels. Longitudinal studies are also
important to validate our results.
Conclusions
In conclusion, the present study suggests that baseline
serum KL-6 level (both as continuous value and at the cut-
off level of 1300 U/mL) is a sensitive predictor for the
onset of AE-IPF. Future studies are necessary to confirm the
clinical utility of baseline KL-6 measurement for the pre-
diction of AE in patients with IPF.
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